Published in Eur Urol on March 01, 2004
Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol (2010) 1.12
Defining the role of NMP22 in bladder cancer surveillance. World J Urol (2007) 1.10
Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol (2008) 1.05
Individual risk assessment in bladder cancer patients based on a multi-marker panel. J Cancer Res Clin Oncol (2012) 0.81
Update on intravesical agents for non-muscle-invasive bladder cancer. Immunotherapy (2010) 0.76
Urinary markers in screening patients with hematuria. World J Urol (2007) 0.75
BAP1 loss defines a new class of renal cell carcinoma. Nat Genet (2012) 4.97
Race and gender differences in C-reactive protein levels. J Am Coll Cardiol (2005) 3.51
HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A (2004) 3.43
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol (2009) 3.14
Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology (2008) 3.04
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus. Eur Urol (2011) 2.72
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol (2007) 2.66
Urinary diversion. Urology (2007) 2.65
Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol (2006) 2.51
Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation (2005) 2.47
Robotic-assisted laparoscopic extended pelvic lymph node dissection for prostate cancer: surgical technique and experience with the first 99 cases. Eur Urol (2008) 2.42
GreenLight laser vaporization of the prostate: single-center experience and long-term results after 500 procedures. Eur Urol (2008) 2.33
Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol (2011) 2.31
A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. BJU Int (2007) 2.25
Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. Am J Pathol (2002) 2.22
Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol (2008) 2.20
Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol (2005) 2.13
Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. J Urol (2010) 2.11
ROC curves in clinical chemistry: uses, misuses, and possible solutions. Clin Chem (2004) 2.10
Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification. Cancer Biol Ther (2008) 2.09
Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin (2010) 2.05
Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome. Eur Urol (2005) 2.03
Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis. Cancer (2006) 1.92
Is there a role for tamsulosin in the treatment of distal ureteral stones of 7 mm or less? Results of a randomised, double-blind, placebo-controlled trial. Eur Urol (2009) 1.87
Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol (2006) 1.86
Nomograms provide improved accuracy for predicting survival after radical cystectomy. Clin Cancer Res (2006) 1.84
Homozygous deletion of the MTAP gene in invasive adenocarcinoma of the pancreas and in periampullary cancer: a potential new target for therapy. Cancer Biol Ther (2005) 1.83
Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol (2010) 1.83
Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol (2006) 1.82
Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biol Ther (2004) 1.74
Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res (2006) 1.72
Pelvic lymph node dissection during robot-assisted radical prostatectomy: efficacy, limitations, and complications-a systematic review of the literature. Eur Urol (2013) 1.69
BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol (2003) 1.68
Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. Eur Urol (2013) 1.67
Bladder cancer screening in a high risk asymptomatic population using a point of care urine based protein tumor marker. J Urol (2009) 1.66
Laser fibre deterioration and loss of power output during photo-selective 80-w potassium-titanyl-phosphate laser vaporisation of the prostate. Eur Urol (2008) 1.62
uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues. Proc Natl Acad Sci U S A (2006) 1.61
Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int (2010) 1.61
Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol (2010) 1.61
Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. BJU Int (2008) 1.60
Combined magnetic resonance imaging and magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer: a systematic review and meta-analysis. Eur Urol (2008) 1.60
Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. J Urol (2006) 1.60
Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers. J Urol (2011) 1.59
Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation (2005) 1.58
Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. Eur Urol (2010) 1.57
Life-threatening complication after right renal extracorporeal shock wave lithotripsy: large hepatic haematoma requiring embolisation of the right hepatic artery. Eur Urol (2007) 1.57
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res (2004) 1.55
The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephrouretectomy for upper urinary tract urothelial carcinoma. J Endourol (2011) 1.53
Intermediate-term results of retroperitoneoscopy-assisted cryotherapy for small renal tumours using multiple ultrathin cryoprobes. Eur Urol (2006) 1.53
Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicentre assessment of outcome. Eur Urol (2007) 1.52
Urological surgery and antiplatelet drugs after cardiac and cerebrovascular accidents. J Urol (2010) 1.52
Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. J Urol (2007) 1.52
High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients. J Urol (2005) 1.51
Laparoscopy in German urology: changing acceptance among urologists. Eur Urol (2008) 1.51
Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int (2011) 1.50
Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol (2006) 1.50
Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. Urology (2008) 1.50
Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47. Am J Clin Pathol (2002) 1.50
Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. BJU Int (2014) 1.48
The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol (2013) 1.47
Dual-energy computed tomography for the differentiation of uric acid stones: ex vivo performance evaluation. Urol Res (2008) 1.45
Comparison of a multi-layer structural model for arterial walls with a fung-type model, and issues of material stability. J Biomech Eng (2004) 1.45
Seven hours to adequate antimicrobial therapy in urosepsis using isothermal microcalorimetry. J Clin Microbiol (2013) 1.45
Comparative analysis of oncologic outcomes of partial ureterectomy vs radical nephroureterectomy in upper tract urothelial carcinoma. Urology (2013) 1.44
Lateral temperature spread of monopolar, bipolar and ultrasonic instruments for robot-assisted laparoscopic surgery. BJU Int (2014) 1.44
HMGA2 participates in transformation in human lung cancer. Mol Cancer Res (2008) 1.44
Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades. Int J Urol (2012) 1.43
p53 predictive value for pT1-2 N0 disease at radical cystectomy. J Urol (2009) 1.43
Increased toxicity and lack of efficacy of Rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: A phase II study. Int J Cancer (2003) 1.43
The high-mobility group A1 gene up-regulates cyclooxygenase 2 expression in uterine tumorigenesis. Cancer Res (2007) 1.42
Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer (2004) 1.41
Effect of testicular germ cell tumor therapy on renal function. Urology (2012) 1.41
Retroperitoneoscopic living donor nephrectomy: a retrospective comparison to the open approach. Transplantation (2004) 1.39
Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer (2008) 1.39
Potential consequences of low biopsy core number in selection of patients with prostate cancer for current active surveillance protocols. Urology (2013) 1.39
Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: an immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol (2002) 1.39
New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am J Surg Pathol (2008) 1.39
Transitional cell ovarian carcinoma in a BRCA1 mutation carrier. Obstet Gynecol (2002) 1.39
KPNA2 expression is an independent adverse predictor of biochemical recurrence after radical prostatectomy. Clin Cancer Res (2011) 1.38
Is kidney surgery going to be minimally invasive in all cases? Eur Urol (2007) 1.38
Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol (2006) 1.38
Long-term experience with surgical and conservative treatment of penile fracture. J Urol (2004) 1.37
Comparison of potassium-titanyl-phosphate laser vaporization of the prostate and transurethral resection of the prostate: update of a prospective non-randomized two-centre study. BJU Int (2008) 1.37
Claudin 4 protein expression in primary and metastatic pancreatic cancer: support for use as a therapeutic target. Am J Clin Pathol (2004) 1.37
Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol (2003) 1.33